Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT04058639
Recruiting Not applicable

Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?

NCT04058639 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2019-10-01
Last updated
2026-08-14

Condition(s) studied

Diabetic Foot Ulcer

Investigational drug(s) / intervention(s)

"custom felt relief"standard relief treatment

"custom felt relief": Felt is adjusted to the wound by cutting it in different ways and layers once every week

standard relief treatment: Felt in the shape of a letter U is put around the wound once every week.

Study summary

The Surgical Outpatient Clinic at Molde Hospital has since 2015 offered specialized treatment for patients with diabetic foot ulcers. This treatment is given by an interdisciplinary diabetic foot ulcer team. The standard treatment for diabetic foot ulcers is relief, a method with good results.

Although the treatment as usual gives good results, the team wants to optimize this treatment. By using custom felt relief for each patient, the treatment period might be reduced considerably. The aim of this study is therefore to investigate whether custom felt relief gives shorter processing time compared to standard relief treatment.

Eligibility

Sex
ALL
Min age
45 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * diagnosed with Diabetes Mellitus Type 1 or 2 * has neuropathic wounds under the foot * understands and speaks Norwegian well * competent to give consent Exclusion Criteria: * responds to the filament glue and/or the tape used in treatment * in need of vascular surgery intervention * to be admitted to the hospital * in need of intravenously administered antibiotics due to wound infection.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Klinikk for Kirurgi Molde, Helse Møre og Romsdal HF Molde Norway Recruiting

More Helse Møre og Romsdal HF trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04058639 on ClinicalTrials.gov ↗ ← All trials in Norway